The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are: * What kind of local treatment provides a survival benefit for patients with poor prognostic factors? * What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors? * Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors? Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.
Study Type
OBSERVATIONAL
Enrollment
2,000
neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
OS
Overall survival time
Time frame: From date of first follow-up until the date of documented death from any cause, assessed up to 120 months
PFS
Progression-free survival time
Time frame: From date of first follow-up until the date of first documented progression, assessed up to 120 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.